GlassScriptPhysician profile
Melissa Chapel
NPI 1407224819
$3,424.16
in general payments reported to CMS, 2019-2025
27 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $390 · 2022: $516 · 2023: $690 · 2024: $809 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,518.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $973.08 | 2023-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Clinical Trial Product |
| Scilex Pharmaceuticals INC. | $382.44 | 2021-2024 | Ztlido |
| Ibsa Pharma INC. | $307.28 | 2021-2025 | Tirosint, Tirosint, Licart |
| Collegium Pharmaceutical, INC. | $227.91 | 2021-2025 | Xtampza, Belbuca |
| Globus Medical, INC. | $196.72 | 2025 | Senza |
| Azurity Pharmaceuticals, INC. | $159.31 | 2023-2025 | Horizant, Horizant |
| Medtronic, INC. | $152.10 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Idorsia Pharmaceuticals US INC | $134.84 | 2022-2024 | Quviviq |
| Forte Bio-Pharma LLC | $116.36 | 2024 | Prolate, Nalocet |
| Relievant Medsystems, INC. | $106.67 | 2022 | |
| Nevro Corp. | $84.04 | 2023-2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.33 | 2025 | Relistor |
| Averitas Pharma INC. | $64.46 | 2023-2025 | Qutenza |
| Biodelivery Sciences International, INC. | $62.50 | 2021 | |
| Pfizer INC. | $60.86 | 2021-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $55.17 | 2021-2022 | |
| Bioventus LLC | $46.08 | 2022-2023 | Durolane |
| Hikma Pharmaceuticals USA | $35.95 | 2022 | |
| Abbott Laboratories | $30.91 | 2021-2023 | Proclaim |
| Lilly USA, LLC | $24.95 | 2021-2022 | |
| Biotronik Nro, INC. | $24.74 | 2025 | Prospera |
| Masimo Corporation | $24.43 | 2023 | Patient Safetynet System |
| Pacira Pharmaceuticals Incorporated | $20.92 | 2025 | Iovera, Zilretta |
| Vertex Pharmaceuticals Incorporated | $20.35 | 2025 | |
| Curonix LLC | $18.40 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Horizon Therapeutics Plc | $15.08 | 2022 | |
| Avanos Medical | $13.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Chapel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.